Life Science News

Johnson & Johnson to Participate in the Barclays Global HealthCare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global HealthCare Conference on Tuesday, March 14 th , at the Loews Miami Beach Hotel, Miami Beach, Florida. Aldo Denti, Company Group Chairman DePuy Synthes and Peter Menziuso, Company Group Chairman, Vision will represent the Company in a session scheduled at 10:15 a.m. (Eastern Time).

This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com .

The audio webcast replay will be available approximately 48-hrs after the webcast.

Investor Contact:
RA-JJCUS-InvestorRel@ITS.JNJ.com

Media Contact:
Tesia Williams, TWilli65@ITS.JNJ.com

News Provided by Business Wire via QuoteMedia

JNJ
The Conversation (0)

Kaleido Collaborates with Janssen on Metabolic Therapies

Kaleido Biosciences (NADAQ:KLDO) announced a research collaboration with Janssen’s World Without Disease Accelerator, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE:JNJ).

As quoted in the press release:

Keep reading...Show less

XBiotech Sells Human Antibody to Janssen for US$750 Million

XBiotech (NASDAQ:XBIT) announced the closing of the sale of its True Human antibody Bermekimab to Johnson & Johnson’s (NYSE:JNJ) Janssen Biotech.

As quoted in the press release:

Keep reading...Show less
CSE:BOSS

YIELD GROWTH Announces 130 Retail Locations Confirmed to Sell Urban Juve Products

The Yield Growth Corp. (CSE:BOSS, OTCQB:BOSQF, Frankfurt:YG3) is pleased to announce that 130 retail locations across Canada and the US have agreed to sell Urban Juve products with 90 retail locations now live with product. The locations are diverse geographically, and will bring luxury, hemp-powered skincare products to new markets across North America.

Keep reading...Show less

Aduro Biotech Announces Initiation of Phase 1b Clinical Trial in Non-Small Cell Lung Cancer under Janssen Strategic Partnership

Aduro Biotech (NASDAQ:ADRO) announced the recent initiation of a Phase 1b study of ADU-214 (JNJ-64041757) in combination with nivolumab for the treatment of advanced lung cancer. ADU-214 is an immunotherapy based on Aduro’s live, attenuated double-deleted Listeria (LADD) technology platform in development for the treatment of advanced or metastatic non-small cell lung cancer. Janssen Biotech, Inc. (Janssen), Aduro’s license partner for ADU-214, is conducting the global trial.

As quoted in the press release:

Keep reading...Show less

Minerva Neurosciences to Report First Quarter 2016 Financial Results and Business Updates on May 3, 2016

| Source:Minerva Neurosciences, Inc.



WALTHAM, Mass., April 26, 2016 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the first quarter of 2016 on Tuesday, May 3, 2016.  The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates.
The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 74086869.  A live webcast of the conference call will be available online in the Investors and Media section of the Company’s website at ir.minervaneurosciences.com.  The archived webcast will be available on the Company’s website beginning approximately two hours after the event for 30 days.
About Minerva Neurosciences:
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases.  Minerva’s proprietary compounds include: MIN-101, in Phase IIb development for schizophrenia; MIN-202 (JNJ-42847922), which recently completed Phase IIa and Phase Ib clinical trials for insomnia and major depressive disorder (MDD), respectively; MIN-117, in Phase IIa development for MDD; and MIN-301, in pre-clinical development for Parkinson’s disease.  Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.”  For more information, please visit www.minervaneurosciences.com.






Keep reading...Show less

Seeking Answers About Transgender Heart Health

Abbott

Abbott

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Don't Mess with Your 'Melon': Abbott and the Brain Injury Association of America Urge 'If You Hit Your Head, Get it Checked' in New Public Service Announcement

  • The Concussion Awareness Now campaign raises awareness both about the common, everyday ways concussions most often happen and the importance of getting concussions evaluated
  • Concussion Awareness Now is a coalition of nearly 20 advocacy groups, founded by Abbott and the Brain Injury Association of America, with Rebel Wilson as the group's inaugural spokesperson
  • The campaign addresses the fact that more than half of people who suspect they have a concussion never get it checked and features a family of characters called the Melons

Concussion Awareness Now, a coalition of nearly 20 advocacy groups founded by Abbott (NYSE: ABT) and the Brain Injury Association of America, unveiled today a new public service campaign to draw attention to concussions and the importance of seeking care.

Experience the interactive Multimedia News Release here: https://www.multivu.com/players/English/9143051-abbott-dont-mess-with-your-melon-the-concussion-awareness-now-campaign/

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Knight Therapeutics Reports Fourth Quarter and Year-End 2022 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company"), a leading Pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2022. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.

Financial information as at and for the year ended December 31, 2022 is unaudited.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Talc Plaintiffs Will Press to Reopen Courthouse Doors

In denying Motion for Rehearing, Third Circuit affirms J&J's 'Texas Two-Step' bankruptcy
was not filed in good faith

The U.S. Court of Appeals for the Third Circuit has denied a request for a rehearing of the LTL bankruptcy petition, signaling a move to reopen litigation against Johnson & Johnson (NYSE:JNJ) based on claims that the company's talcum powder products are linked to ovarian cancer and mesothelioma.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Abbott: Clean, Accessible Water for a Healthy Future

Abbott

Water sustains life, health, and ecosystems. It's a vital resource for a global healthcare company striving to help people around the world live healthier, fuller lives.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Medtronic to boost AI innovation with new platform introduction

A strategic collaboration with Cosmo Pharmaceuticals and NVIDIA delivers the GI Genius™ AI Access™ platform designed to accelerate AI innovation for healthcare.

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced Cosmo Pharmaceuticals and NVIDIA plan to integrate NVIDIA's AI technologies into the GI Genius™ intelligent endoscopy module — the first FDA-cleared, AI-assisted colonoscopy tool to help physicians detect polyps that can lead to colorectal cancer.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×